{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028650","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.222268+00:00","generated_at":"2026-05-26T16:32:51.199625+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Stoke and Biogen enter $165M upfront collaboration for zorevunersen (Dravet syndrome)","bullets":["Stoke receives $165M upfront; eligible for up to $385M in milestones and low-double-digit to high-teen royalties.","Stoke retains exclusive rights in US, Canada, Mexico; Biogen gets rest-of-world commercialization rights.","Phase 3 EMPEROR study to start Q2 2025 with pivotal data readout expected 2H 2027.","Cash runway extended to mid-2028, including upfront payment and other eligible cash flows.","Zorevunersen has FDA Breakthrough Therapy designation; Phase 1/2a showed substantial seizure reduction and cognitive improvements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028650","json":"https://secwatch.observer/filing/0001193125-25-028650.json","markdown":"https://secwatch.observer/filing/0001193125-25-028650.md","text":"https://secwatch.observer/filing/0001193125-25-028650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525028650/0001193125-25-028650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525028650/d889348d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:32:51.199625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}